• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus.AZD5206 对金黄色葡萄球菌的体外药效学研究
Antimicrob Agents Chemother. 2013 Feb;57(2):1062-4. doi: 10.1128/AAC.01208-12. Epub 2012 Dec 10.
2
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.在一种小鼠大腿感染模型中，研究了新型噁唑烷酮类抗生素磷酸托唑烷（TR-701）对甲氧西林敏感和耐药金黄色葡萄球菌菌株的体内药效学。
Antimicrob Agents Chemother. 2011 Jul;55(7):3453-60. doi: 10.1128/AAC.01565-10. Epub 2011 Apr 18.
3
In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.万古霉素和头孢唑林单独及联合应用对耐甲氧西林金黄色葡萄球菌的体外药效学研究。
Antimicrob Agents Chemother. 2012 Jan;56(1):202-7. doi: 10.1128/AAC.05473-11. Epub 2011 Oct 17.
4
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.使用体外模型比较头孢比普与万古霉素对耐甲氧西林金黄色葡萄球菌（MRSA）、万古霉素中介金黄色葡萄球菌（VISA）和耐万古霉素金黄色葡萄球菌（VRSA）的药效学活性。
J Antimicrob Chemother. 2009 Aug;64(2):364-9. doi: 10.1093/jac/dkp176. Epub 2009 May 19.
5
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.头孢洛林的药效学活性对比社区获得性和医疗机构获得性耐甲氧西林金黄色葡萄球菌、异质性万古霉素中介金黄色葡萄球菌、万古霉素中介金黄色葡萄球菌和万古霉素耐药金黄色葡萄球菌，采用的是体外模型。
J Antimicrob Chemother. 2011 Jun;66(6):1301-5. doi: 10.1093/jac/dkr110. Epub 2011 Mar 23.
6
In vitro susceptibility patterns of methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus corneal isolates to antibiotics.耐甲氧西林金黄色葡萄球菌和凝固酶阴性葡萄球菌角膜分离株对抗生素的体外药敏模式。
Cornea. 2010 Oct;29(10):1131-5. doi: 10.1097/ICO.0b013e3181d2ce25.
7
The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.在体外感染模型中研究了磷霉素对金黄色葡萄球菌的药效学。
Int J Antimicrob Agents. 2020 Jul;56(1):105985. doi: 10.1016/j.ijantimicag.2020.105985. Epub 2020 Apr 21.
8
Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.替拉万星治疗兔实验性主动脉瓣心内膜炎的疗效，该模型由耐甲氧西林金黄色葡萄球菌（daptomycin 不敏感株）引起。
Antimicrob Agents Chemother. 2012 Nov;56(11):5528-33. doi: 10.1128/AAC.00922-12. Epub 2012 Aug 13.
9
Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.奥马环素对中性粒细胞减少症小鼠大腿感染模型中金黄色葡萄球菌的药效学研究。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00624-19. Print 2019 Jul.
10
Impact of accessory gene regulator (agr) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus.加拿大社区和医疗保健相关耐甲氧西林金黄色葡萄球菌中辅助基因调节因子 (agr) 功能障碍对万古霉素药效动力学的影响。
Ann Clin Microbiol Antimicrob. 2011 May 20;10:20. doi: 10.1186/1476-0711-10-20.

引用本文的文献

1
Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.新型双重细菌 DNA II 拓扑异构酶抑制剂的抗菌活性。
PLoS One. 2020 Feb 19;15(2):e0228509. doi: 10.1371/journal.pone.0228509. eCollection 2020.
2
In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.在中性粒细胞减少小鼠大腿模型中，针对肺炎链球菌和金黄色葡萄球菌，对两种细菌拓扑异构酶抑制剂ACT - 387042和ACT - 292706进行体内药效学靶点研究。
Antimicrob Agents Chemother. 2016 May 23;60(6):3626-32. doi: 10.1128/AAC.00363-16. Print 2016 Jun.
3
Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.用于体外静态时间杀灭研究中量化细菌杀灭和再生长的新型速率-面积-形状建模方法。
Antimicrob Agents Chemother. 2015 Jan;59(1):381-8. doi: 10.1128/AAC.04182-14. Epub 2014 Nov 3.
4
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.NBTI 5463是一种新型的细菌II型拓扑异构酶抑制剂，对革兰氏阴性菌具有活性且在体内具有疗效。
Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24.
5
Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.通过脂质体制剂改善新型 IIa 拓扑异构酶抑制剂的药代动力学和体内抗菌疗效。
Antimicrob Agents Chemother. 2013 Oct;57(10):4816-24. doi: 10.1128/AAC.00163-13. Epub 2013 Jul 22.

本文引用的文献

1
Optimizing dosage to prevent emergence of resistance - lessons from in vitro models.优化剂量以预防耐药性的出现——来自体外模型的经验教训。
Curr Opin Pharmacol. 2011 Oct;11(5):453-6. doi: 10.1016/j.coph.2011.07.009. Epub 2011 Aug 23.
2
Impact of recA on levofloxacin exposure-related resistance development.RecA 对左氧氟沙星暴露相关耐药性发展的影响。
Antimicrob Agents Chemother. 2010 Oct;54(10):4262-8. doi: 10.1128/AAC.00168-10. Epub 2010 Jul 26.
3
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.药物暴露强度和治疗持续时间对金黄色葡萄球菌对喹诺酮类抗菌药物耐药性产生的影响。
J Infect Dis. 2007 Jun 15;195(12):1818-27. doi: 10.1086/518003. Epub 2007 May 2.
4
Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.庆大霉素对金黄色葡萄球菌和铜绿假单胞菌的比较药效学
Antimicrob Agents Chemother. 2006 Aug;50(8):2626-31. doi: 10.1128/AAC.01165-05.
5
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.有害病菌需要药物：美国传染病学会抗菌药物可及性特别工作组研发进展最新情况
Clin Infect Dis. 2006 Mar 1;42(5):657-68. doi: 10.1086/499819. Epub 2005 Jan 25.
6
Overview of nosocomial infections caused by gram-negative bacilli.革兰氏阴性杆菌引起的医院感染概述。
Clin Infect Dis. 2005 Sep 15;41(6):848-54. doi: 10.1086/432803. Epub 2005 Aug 16.
7
Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.金黄色葡萄球菌和铜绿假单胞菌接种量对氟喹诺酮类和碳青霉烯类药物体外活性及体内疗效的影响。
J Antimicrob Chemother. 2005 Jul;56(1):91-6. doi: 10.1093/jac/dki163. Epub 2005 May 12.
8
The inoculum effect: fact or artifact?接种物效应：事实还是假象？
Diagn Microbiol Infect Dis. 2004 Dec;50(4):229-30. doi: 10.1016/j.diagmicrobio.2004.07.006.

AZD5206 对金黄色葡萄球菌的体外药效学研究

In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus.

机构信息

Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, Texas, USA.

出版信息

Antimicrob Agents Chemother. 2013 Feb;57(2):1062-4. doi: 10.1128/AAC.01208-12. Epub 2012 Dec 10.

DOI:10.1128/AAC.01208-12
PMID:23229481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3553694/
Abstract

AZD5206 is a novel antimicrobial agent with potent in vitro activity against Staphylococcus aureus. We evaluated the in vitro pharmacodynamics of AZD5206 against a standard wild-type methicillin-susceptible strain (ATCC 29213) and a clinical strain of methicillin-resistant S. aureus (SA62). Overall, bacterial killing against a low baseline inoculum was more remarkable. Low dosing exposures and/or high baseline inoculum resulted in early reduction in bacterial burden, followed by regrowth and selective amplification of the resistant population.

摘要

AZD5206 是一种新型抗菌药物，对金黄色葡萄球菌具有强大的体外活性。我们评估了 AZD5206 对标准野生型耐甲氧西林敏感株（ATCC 29213）和耐甲氧西林金黄色葡萄球菌（SA62）临床株的体外药效动力学。总体而言，针对低基线接种物的杀菌效果更为显著。低剂量暴露和/或高基线接种物导致细菌负荷的早期减少，随后是耐药种群的重新生长和选择性扩增。